⌕
Corcept Therapeutics · CORT · Nasdaq
Tenet 54 · Mixed
Compare
$70.07+1.23%At closeTenet 54 · Mixed
$70.07+0.85 (+1.23%)
At close: Nov 17, 2026, 4:00 PM ET· Nasdaq · USD

Corcept Therapeutics (CORT) Stock

Corcept Therapeutics (CORT) closed at $70.07 on Nov 17, 2026; its Tenet Score is 54 of 100 against 340 Healthcare peers.

Sources Company filings, market prices and computed by Tenet Filings, prices and TenetScore as of How we compute thisNot investment advice

5 figures withheld by our checks. Each blank figure names its reason.

Key stats

Close
$70.07
Nov 17, 2026
Market cap
$7.6B
share price × the latest quarter's diluted weighted-average share count (vendor)
P/E
53.5×
TTM through Sep 30, 2026 · as of close, Nov 16, 2026
52-week range
28.66 – 126.38
low → high · as of close, Nov 16, 2026
Tenet Score
54/100
Mixed · 340 Healthcare peers

Industry: Drugs

Corcept Therapeutics Inc scores 54/100. Mixed. Strongest on quality and financial health, value is the soft spot, trading at 54× earnings versus 340 Healthcare peers.

Tenet Score · vs sector

n=340
54/ 100
Mixed
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value
19
Quality
71
Health
69
Growth
55

Factor grades

Grid rings: 25 · 50 · 75 · 100 percentile
ValueFQualityBHealthCGrowthCMomentumB
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Show the math →

Price

Loading chart…
P/B
9.1×
Sep 30, 2026 balance sheet
P/S
7.9×
price to sales, TTM through Sep 30, 2026 · as of close, Nov 16, 2026
ROE
22%
TTM through Sep 30, 2026
Operating margin
5.9%
fiscal 2025, before interest and tax
Net margin
16.8%
TTM through Sep 30, 2026
Current ratio
3.00
Sep 30, 2026 balance sheet
Net debt / EBITDA
−3.4×
TTM through Sep 30, 2026
EPS CAGR 5y
—
This growth figure starts in a period outside the history your plan includes.
Div yield
—
no yield on file

The whole report, at a glance · every card is a live peek, click any to open the section

About Corcept Therapeutics Inc

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medi…

Composite computed Nov 16, 2026 · peer basis: Healthcare (n=340) · every glimpse links to its full section with sources · not investment advice.

ETF exposure

held by 151 US ETFs · top wrappers by weightSee all ETFs holding CORT →

Similar-sized companies in Drugs

The 10 companies in this industry closest in market cap, as of Nov 16, 2026.

What sector and industry is Corcept Therapeutics in?

Corcept Therapeutics is in the Healthcare sector and the Drugs industry.

What is Corcept Therapeutics' Tenet Score?

Corcept Therapeutics' Tenet Score is 54 out of 100, ranked against 340 Healthcare peers as of Nov 16, 2026.

Install Tenet on your phone

Tenet home pageMethodology© 2026 Tenet Investing Inc.

Data from Intrinio and Financial Modeling Prep.